Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D. DiNardo, Marina Konopleva, Jörge E. Cortes et al.|American Journal of Hematology|2017Cited by 437